CLIA Waiver for QuickVue® RSV Test
go back to news archives| Quidel Corporation has announced that the U.S. Food and Drug Administration (FDA) granted CLIA waiver for the QuickVue® RSV test for the qualitative detection of respiratory syncytial virus (RSV). The waiver makes the QuickVue RSV test more widely available for use, especially in physician offices and clinics where waived tests are used most frequently. The QuickVue RSV test is simple and accurate, with high sensitivity and specificity. Respiratory syncytial virus is recognized by the American Academy of Pediatrics as the leading cause of pneumonia and bronchiolitis among children two years of age and younger. RSV is a common virus with symptoms that often resemble the common cold. The QuickVue RSV test is intended for use as an aid in the diagnosis of acute RSV viral infections for symptomatic pediatric patients. |
NOTE: This item is from our 'historic' database and
may contain information which is not up to date.
Source : Quidel Corporation View Company Information
Posted on March 7, 2008
advertisement
advertisement
advertisement
advertisement
LATEST MICROBIOLOGY NEWS
MICROBIOLOGY EVENTS
-
USP Chapter <86> and the Move to Recombinant Methods
-
2025 Novogene Sequencing Symposium
-
Explore the Future of Sterility Testing with Rapid Micro Biosystems®
-
Understanding USP <73> to Accelerate Sterility Testing for Short-Life Products
-
British Society For Microbial Technology 40th Anniversary Microbiology Conference
-
How Is VIDAS® KUBE™ Transforming Food Pathogen Detection?
-
Sampling and Microbial Testing of Water and Data Trending
-
European Microbiology Conference and Workshop 2025
-
Future Labs Live 2025
-
2025 Endotoxin Testing Summit
